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Liver regeneration: a spotlight on the novel role of platelets and
serotonin
Abstract
The development of novel approaches in liver surgery in the last decade has saved the lives of a large
number of patients via resection of liver tumours previously thought to be non-resectable. Concurrently,
living donor liver transplantation has emerged as one of the ways of lowering mortality on the waiting
lists. These breakthroughs demanded a rigorous understanding of the mechanisms of liver regeneration
after partial hepatectomy. Based on our previous studies on blood platelets and cold ischaemic injury,
platelets and serotonin have attracted attention due to their theoretical potential contribution to liver
regeneration. Both platelets and serotonin have been proven to be crucially involved in liver
regeneration after partial hepatectomy. This review article provides an overview on the process of liver
regeneration, with emphasis on its molecular basis and the coordinate contribution of several cells to
restoring the organ's original volume and function. The role of platelets and serotonin is highlighted as
novel contributors in this process.
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Liver regeneration: a spotlight on the novel
role of platelets and serotonin 
Pierre-Alain Clavien 
Swiss HPB (Hepato-Pancreatico-Biliary) Centre, Department of Surgery, University Hospital Zurich,
Zurich, Switzerland
The development of novel approaches in liver
surgery in the last decade has saved the lives of a
large number of patients via resection of liver tu-
mours previously thought to be non-resectable.
Concurrently, living donor liver transplantation
has emerged as one of the ways of lowering mor-
tality on the waiting lists. These breakthroughs
demanded a rigorous understanding of the me-
chanisms of liver regeneration after partial hepa-
tectomy. Based on our previous studies on blood
platelets and cold ischaemic injury, platelets and
serotonin have attracted attention due to their
theoretical potential contribution to liver regene-
ration. Both platelets and serotonin have been
proven to be crucially involved in liver regenera-
tion after partial hepatectomy. This review article
provides an overview on the process of liver rege-
neration, with emphasis on its molecular basis and
the coordinate contribution of several cells to re-
storing the organ’s original volume and function.
The role of platelets and serotonin is highlighted
as novel contributors in this process.
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Summary
There have been many breakthroughs in the
field of liver surgery over the past decade with the
realisation that liver resection is the only cure for
liver tumours in many patients. This has resulted
in novel surgical strategies involving removal of
more than 70% of the liver, with the need in some
cases sometimes to manipulate the liver vol-
 ume prior to surgery to enable growth of the 
healthy liver and atrophy of the part containing a
tumour [1]. Similar progress has occurred in the
field of liver transplantation, where the lack of
available organs and the increasing number of pa-
tients with liver diseases dying on the waiting list
has triggered a search for alternative strategies [2].
Living donor liver transplantation has emerged 
as an effective means of increasing the organ 
pool. This procedure involves a major liver resec-
tion (right hemiliver = 50–60% of the liver) in a
healthy adult [3]. While the liver has the unique
ability to regenerate in a few days or weeks after
major tissue loss, major liver resection both in pa-
tients with liver tumours or for organ donation
involves the risk of liver failure due to insufficient
liver mass. Below a certain threshold (about 
20–25%) the remnant liver cannot regenerate,
leading to the liver failure called “small-for-size
syndrome” – meaning that a remnant liver is too
small for the size of an individual [1, 4]. 
Small-for-size syndrome is the single most
important limiting factor in liver surgery and
transplantation. Strategies to prevent liver failure
have been the focus of many groups, and a break-
through will likewise occur only through an im-
proved understanding of the many pathways of
liver regeneration. We have summarised the cur-
rent advances in liver surgery in a recent review
article published in the New England Journal of
Medicine [1]. This has been a major focus for our
laboratory and the clinical research of my groups
Introduction
Abbreviations:
EGF epidermal growth factor 
HGF hepatocyte growth factor 
IL-6 interleukin-6 
PDGF platelet-derived growth factor 
NF-k B nuclear factor-kappa B 
SERT serotonin reuptake transporter 
STAT 3 signal transducer and activator of transcription 3 
TPO thrombopoietin 
TGF-a & b transforming growth factor alpha & beta 
TPH tryptophan hydroxylase 
TNF-a tumour necrosis factor alpha 
VEGF vascular endothelial growth factor 
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for about a decade. In this article, I will first cover
some current knowledge of liver regeneration and
then present our recent and ongoing work on the
role of serotonin and platelets in initiating liver
regeneration. 
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An overview of liver regeneration
The human body responds to partial hepatec-
tomy by reestablishment of the original volume of
the organ thanks to the unique ability of the liver
cells to replicate and increase the remnant
 segments. The typical scenario of liver volume re-
storation commences with hyperplasia of various
types of intrahepatic cells followed by a phase of 
cellular hypertrophy [1]. This phenomenon is 
traditionally known as liver regeneration despite
the fact that, in purely biological terminology, nei-
ther hyperplasia nor hypertrophy is a synonym for
regeneration [5]. 
Fundamental characteristics of liver 
regeneration
Several experimental methodologies have been
applied to the study of liver regeneration. Rodent
models of partial hepatectomy have provided the
most convenient approach to study this process, 
given their close resemblance to the human situa-
tion, absence of immediate tissue injury or inflam-
mation and precise definition of the initial time
point when liver regeneration is triggered [1, 6]. In
a normal murine liver mature differentiated hepa-
tocytes exhibit minimal turnover [7] with only one
out of 2000–3000 hepatocytes dividing under phy-
siological conditions to maintain normal liver mass
[8]. The extent of the resection and tissue  damage
remarkably influence the initiation and synchroni-
sation of replication in different types of hepatic
cells. For instance, minor damage (eg toxic 
or ischaemic injury) or a relatively small resection
(removal of less than 30% of the liver) results in a
less powerful replication rate, which is also less syn-
chronised in comparison with a major resection (re-
moval of 70% of the liver) [8, 9]. After a massive 
resection, up to 90% of the hepatocytes appear to
replicate [9]. There is significant variation among
species with regard to the onset and peak of hepa-
tocyte replication [1]. In human beings, replication
of hepatocytes generally begins within 1 day after a
major resection. Endothelial cells, Kupffer cells and
bile duct cells replicate in delayed fashion. Several
additional days are then required for growth, dur -
ing which enhancement of cell size occurs [1]. In
mice, deoxyribonucleic acid (DNA) replication af-
ter partial hepatectomy peaks 44–48 hours after the
operation, regardless of the time of the day at which
the procedure has been performed (fig. 1). The en-
try of cells that had replicated their DNA into mi-
tosis always occurs at the same time of day [10–12].
It has been suggested that proliferating hepato-
cytes provide the mitogenic stimuli required for pro-
liferation of the other cells [6]. Hence nonparen-
chymal cells, such as endothelial cells, Kupffer cells,
and biliary-duct cells, replicate in delayed fashion
[1]. DNA synthesis is completed in 72 hours. At this
time the inhibitory action of TGF b1 on liver regen -
eration predominates [13]; allowing for changes 
in liver histology [6]. At post-hepatectomy day 3 to
4, clumps of small hepatocytes penetrated by
 processes from Ito cells are observed around newly
formed capillaries [14]. These small hepatocyte
clumps are to be reorganised into the characteristic
hepatocyte plates of the mature liver, while the cap -
illaries change into sinusoids lined by fenestrated
endothelium and Kupffer cells [6]. Eventually the
liver should reach the normal liver/body mass ratio
to enable proper function, even if a small-sized graft
is implanted into a larger recipient [15–17]. 
Basic molecular pathways of liver
 regeneration
Liver regeneration encompasses activation of
many intra- and extracellular molecules and path-
ways (fig. 2). The current concept is that there are
cytokine and growth factor-mediated networks
promoting regeneration of various types of intra-
hepatic cells. Many factors pertaining to liver regen -
eration have been extensively studied, among
which serotonin and platelets have recently made
exciting advances and will be discussed in later
 sections. Precise integration of growth signals is
 required for full and synchronised regeneration.
Failure to activate these signaling cascades may
 result in delay of the onset of regeneration, inade-
quate recovery of liver volume and eventually
 clinical signs of liver failure [18].
Cytokine-mediated pathways
Partial hepatectomy stimulates expression of
many genes which are involved in a cytokine net-
work. Several studies have demonstrated that the
release of cytokines during the early post-hepatec-
tomy period is critical for initiation of liver regen -
eration. The cytokine action is initiated through 
Figure 1
Kinetics of DNA syn-
thesis in hepatocytes,
biliary ductular cells,
Kupffer, Ito and sinu-
soidal endothelial
cells. [Adapted from:
Michalopoulos GK,
DeFrances MC. 
Liver regeneration.
Science. 1997;276
(5309):60–6 and
reprinted with
 permission.]
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binding of tumour necrosis factor-a (TNF-a) to its
 receptor TNFR1, resulting in activation of NF-k
B (nuclear factor-k B) in non-parenchymal cells. In
addition it causes release of interleukin-6 (IL-6)
and activation of signal transducer and activator of
transcription 3 (STAT3) in hepatocytes [19]. Lipo-
polysaccharide (LPS) which is released from enter -
ic bacteria into the portal circulation has been sug-
gested as a principal trigger of cytokine network
 activation [20]. Rats with restricted production of
LPS and LPS-hyporesponsive mice have shown
delayed regeneration after partial hepatectomy
[21].
Tumour necrosis factor-a (TNF-a)
Plasma levels of TNF-a which is produced
mainly by Kupffer cells increase after partial hepa-
tectomy. Antibodies against TNF-a administered
at the time of hepatectomy lower the regenerative
response [22]. Liver regeneration is blocked after
partial hepatectomy in mice with genetic deletions
of the TNFR1 [18, 23, 24]. TNF-a is not a direct
stimulant of normal hepatocyte replication and
does not induce DNA synthesis either in primary
cultures of hepatocytes or in vivo [25]. Further-
more, TNF-a enhances the effects of direct mito-
gens such as HGF [26]. Despite convincing evi-
dence indicating a crucial role of TNF-a in liver
regeneration, TNF-a represents only one out of
the many other important molecules which are
concurrently activated and contribute to orches -
trating the early events after partial hepatectomy
[25].
Interleukin-6 (IL -6)
IL-6 is chiefly produced by Kupffer cells,
which represent resident hepatic macrophages
[27]. Following partial hepatectomy plasma levels
are transiently increased [28]. Several studies have
shown that IL-6 is necessary for proper liver re-
generation [29, 30]. However, since restoration of
liver mass is only delayed in the absence of IL-6, it
does not appear to be the main inducer of this
 process [29]. IL-6 is not a direct mitogen for
 hepatocytes and does not enhance the mitogenic
effect of other growth factors. Nonetheless, IL-6
exerts a mitogenic influence on biliary cells [31] and
rescues failure of liver regeneration in the ischae-
mic [32] and fatty liver [33]. Moreover, IL-6 influ-
ences the integrity of the intrahepatic biliary tree
by regulating production of small proline-rich pro-
teins by cholangiocytes [34, 35]. Hence, similarly
to TNF-a, IL-6 is probably a contributory factor
in optimising but not initiating the processes of
liver regeneration.
Growth factor-mediated pathways
There is a consensus that no single molecule is
able to induce liver regeneration after partial he-
patectomy. Several growth factors are involved in
stimulating the liver to regenerate, eg hepatocyte
growth factor (HGF), epidermal growth factor
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Figure 2
After hepatectomy, nonparenchymal cells, such as stellate cells, Kupffer cells, leukocytes, and platelets, are activated by solu-
ble factors such as vascular endothelial growth factor and lipopolysaccharide. Interaction between activated vascular compo-
nents, including platelets, leukocytes, sinusoidal endothelial cells and Kupffer cells, results in the release of tumour necrosis
factor a, interleukin-6, and serotonin. The cytokines cause priming of the remnant hepatocytes and, concurrently, extracellular
proteases such as urokinase-type plasminogen activator convert inactive hepatocyte growth factor to its active form. Inactive
hepatocyte growth factor, which is secreted by stellate cells, is a mitogen that induces hepatocyte proliferation. Matrix metal-
loproteases convert membrane-bound transforming growth factor a into the soluble form. In an autocrine loop, transforming
growth factor, along with endothelial growth factor, signals through the endothelial growth factor receptor. The cytokines 
and the growth factors act in concert to initiate the reentry of quiescent hepatocytes (in the G0 phase) into the cell cycle from
the G1 phase to the S phase, resulting in DNA synthesis and hepatocyte proliferation. To signal the end of proliferation, trans-
forming growth factor b blocks further replication. The metabolic load resulting from the loss of hepatocytes is indicated by
the accumulation of bile acids in the blood. The bile acids enter the hepatocytes and drive bile acid receptors such as the
 farnesoid X receptor, resulting in increased protein and DNA synthesis [Adapted from: Clavien PA, et al. Strategies for safer
liver surgery and partial liver transplantation. N Engl J Med. 2007;356(15):1545–59; © 2007 Massachusetts Medical Society. 
All rights reserved.]
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(EGF), vascular endothelial growth factor (VEGF)
and platelet-derived growth factor (PDGF). Seve-
ral investigators have identified TGF b1 as the main
inhibitor of liver regeneration. We will focus on
HGF, EGF and TGF b1 as the most important key
players. 
Hepatocyte growth factor (HGF)
HGF is synthesised by non-parenchymal cells,
particularly stellate cells, and therefore affects he-
patocytes in a paracrine manner [9]. It is present in
the extracellular matrix in relatively large quanti-
ties as inactive precursor [36, 37]. Activation by
proteases results in a 10- to 20-fold increase in
plasma HGF levels [38]. Systemically injected
HGF is trapped mainly by the liver [39]. HGF 
injection into the portal vein of normal rats and
mice causes proliferation of hepatocytes and en -
largement of the liver [40, 41]. The intrahepatic re-
serve of HGF is consumed during the first three
hours after partial hepatectomy, followed by new
HGF synthesis [42]. HGF exerts a direct mito genic
effect on hepatocytes. HGF administration results
in events similar to those occurring during liver re-
generation, including massive hepatic enlarge-
ment, and triggers a strong mitogenic response and
clonal expansion of hepatocytes in culture [43].
HGF signals through cMet (HGF receptor), which
is expressed in most epithelial cells, endothelial
cells and neurons, and mediates all the effects of
HGF [44]. Liver HGF receptor becomes activated
30–60 min after partial hepatectomy [45]. Genetic
deletion of cMet from the liver has been shown to
abolish liver regeneration [46]. HGF has therefore
been described as an “irreplaceable contributor” to
liver regeneration [28].
Epidermal growth factor (EGF)
Experiments in rats have suggested that EGF
may be involved in liver regeneration. Surgical re-
moval of major salivary glands [47], where EGF is
present in high concentrations [48], or ligation of
their draining veins significantly decreases the
DNA synthesis peak after partial hepatectomy
and results in impaired liver regeneration [47].
Exogenous injection of EGF compensates the ef-
fects of salivary gland ablation and restores liver
regeneration [47]. EGF is normally supplied by
Brunner’s glands of the duodenum through the
portal circulation [49] to be deposited in the peri-
portal matrix [50]. EGF is thought to have mito-
genic potential in liver regeneration given its ab-
rupt availability to hepatocytes after partial hepa-
tectomy. Resection of 2⁄3 of hepatic parenchyma
increases the concentration of EGF per unit liver
weight by a factor of three despite only slight 
elevation of plasma EGF concentrations [47]. 
Transforming growth factor b1 (TGF b1)
Similarly to other cytokines involved in liver
regeneration, plasma TGF b1 levels also rise very
shortly after partial hepatectomy [25]. TGF b1 is
produced predominantly by hepatic stellate cells
(myofibroblasts) [51]. TGF b1 is known to have
growth inhibitory effects on liver regeneration, 
eg it inhibits proliferation of hepatocytes in cell
culture [52], suppresses production of HGF [53]
and activation of HGF receptors [54]. High doses
of TGF b1 result in delay or partial suppression of
DNA synthesis after partial hepatectomy [55].
However, a decrease in the expression of TGF b1
receptors in the first 48 hours after partial hepa-
tectomy seems to enable the hepatocytes to resist
the regeneration-inhibitory effects of TGF b1 dur -
ing this period [52, 56]. Other factors may in-
clude the high levels of norepinephrine following
partial hepatectomy or enhanced production of
TGF-a by regenerating hepatocytes [57]. Re-
gardless of its potential as a regeneration termina-
tor, TGF b1 is thought to play an important role
in the assembly of hepatic tissue towards the end
of regeneration. TGF b1 stimulates production of
numerous extracellular matrix proteins in many
tissues, including the liver. TGF b1 also stimulates
tubulogenesis and formation of neovascular struc-
tures in endothelial cells in collagen gels [58, 59].
Concomitant with the peak of TGF b1 synthesis
at the end of regeneration, new extracellular ma-
trix is synthesised with the appearance of new
 sinusoidal capillary network. Similar events occur
at the end of wound healing with a concurrent
 increase in TGF b1 [28, 60].
Other growth factors with autocrine or paracrine
 effects
Other growth factors appear to be involved 
in liver regeneration, eg TGF-a, VEGF and
PDGF. The complexity of interaction and overlap
between their functional capacities implies that
even in the absence of one of them liver regenera-
tion is likely to continue, albeit at a slower pace. 
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Platelets and liver regeneration
Our interest in the impact of platelets on the
liver dates back to the late nineties. We and others
showed that platelets may significantly enhance he-
patic reperfusion injury after cold ischaemia
[61–63]. On the basis of our previous experiments
we focused on the potential role of platelets in liver
regeneration [64]. Platelets are non-nucleated dis-
coid particles which are essential for haemostasis
and thrombosis [65, 66]. Apart from coagulation,
platelets contribute to the inflammatory reaction
after many forms of tissue injury [67]. 
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Contribution of platelets in liver 
regeneration
The liver and platelets display a very intimate,
albeit complex, interconnection [68]. The liver
plays a critical role even during the synthesis of 
platelets from megakaryocytes through thrombo-
poetin (TPO) [68]. TPO, the most important growth
factor in the regulation of megakaryocyte develop-
ment and platelet production, is produced mainly
in the liver and kidney [68]. Hence platelets are not
expected to function properly in diseased liver
states [69]. 
A number of proteins which induce opposing
effects on liver regeneration are present in plate-
lets. For instance, platelets harbour important
growth factors for execution of liver regeneration,
eg HGF [1, 70, 71]. Contrariwise, platelets 
contain TGF-a [72, 73] which is required for ter-
mination of liver regeneration [1]. Thus, it is plau-
sible that platelets may participate in orchestrating
liver regeneration through harmonised stimula-
tion and inhibition of growth-related signals.
Until 2006 it was unclear whether platelets are
promoters, inhibitors of, or not even active contri-
butors to, liver regeneration. Many in vitro studies
demonstrated that platelets contain several growth
factors [74] (table 1) which may theoretically con-
tribute to the process of liver regeneration [36, 75].
However, the only in vivo study on the role of 
platelets in liver regeneration in rats failed to iden-
tify a correlation between platelets and liver regen-
eration [76].
In a previous study on regeneration of liver in
rats it was noted that splenectomy increases plate-
let counts and accelerates liver regeneration via an
unclear mechanism [77]. To investigate more clos -
ely the role of platelets in liver regeneration in
mice, we applied inhibitors of platelet function
which remarkably reduced liver regeneration. In a
second step we depleted platelets to less than 5%
by applying a platelet-specific antibody. After 70%
liver resection, these mice exhibited significantly
impaired liver regeneration, suggesting that a fac-
tor contained in platelets may be required to induce
or maintain liver regeneration [64]. In another
study thrombocytotic mice exhibited increased
liver regeneration while a thrombocytopenic
group showed impaired regeneration [78]. Matsuo
et al. reported that direct contact between platelets
and hepatocytes is necessary for the proliferative
effect [79]. These authors concluded that platelet-
hepatocyte contact initiates signal transduction in-
volved in growth factor activation. HGF, VEGF
and insulin-like growth factor-1 were found to con-
tribute chiefly to hepatocyte proliferation [79].
Murata et al. have recently demonstrated that 
platelets promote liver regeneration even under
conditions of Kupffer cell depletion, by stimulating
HGF and insulin-like growth factor-1 expression
[80]. 
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Growth factor Abbreviation  
Epidermal growth factor EGF
Platelet-derived growth factor PDGF
Transforming growth factor-a TGF-a
Transforming growth factor b1 TGF-b1
Keratinocyte growth factor KGF
Fibroblast growth factor-1 FGF-1 
Fibroblast growth factor-2 FGF-2 
Vascular endothelial growth factor VEGF 
Connective tissue growth factor CTGF 
Granulocyte/macrophage 
colony-stimulating factor GM-CSF 
Insulin-like growth factor IGF
Table 1
Growth factors con-
tained in platelets.
[Adapted and modi-
fied from: Rozman P,
Bolta Z. Use of plate-
let growth factors in
treating wounds and
soft tissue injuries.
Acta Dermatovenerol 
Alp Panonica Adriat.
2007;16:156–65.]
Serotonin: the novel participant in liver regeneration
Our studies on the role of platelets in hepatic 
regeneration have raised the question which of the
factors stored and secreted by platelets could be re-
sponsible for platelet-mediated induction of regen -
eration. Exploratory experiments enabled us to 
identify serotonin as one of the crucial factors for
liver regeneration. Serotonin (5-hydroxytrypta-
mine, 5HT) is widely distributed in animals, fungi
and plants, including fruits and vegetables [81]. The
history of serotonin dates back to 1937 when en-
teramine, an enterochromaffin cell-derived sub-
stance, was described by Erspamer [82, 83] as caus-
ing smooth muscle contraction. In 1948, Rapport
and colleagues successfully purified and isolated the
same substance, which has been shown to induce
vasoconstriction, from beef serum, and determined
that it is 5HT. Pointing out its source (serum) and
effect (enhancing vascular tone), the investigators
named this compound serotonin.
Serotonin acts as a physiological mediator of 
gastrointestinal functions (fig. 3), eg regulation of 
intestinal motility. In contrast, serotonin is an 
important component of a variety of pathological
conditions [84–87]. For instance, it is responsible 
for many symptoms related to carcinoid syndrome
[88]. The substantial role of serotonin as a neuro-
transmitter in the central nervous system, as a local
hormone in the peripheral vascular system and the
gastrointestinal tract and as a mediator of brain-gut
connection, is well established [81]. With respect to
the liver, several studies have  already focused at-
tention on the remarkable  impact of serotonin on 
hepatic microvascular perfusion, diameter of hepa-
tic sinusoids, adhesion of platelets and leukocytes to
sinusoidal endothelium [89, 90], hepatic ischae-
mia/reperfusion injury [91] and lodgement of tu-
mour cells in the liver [92]. Almost 7 decades elapsed
until platelet-derived serotonin was introduced by
our group as a key player in liver regeneration [64].
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Serotonin synthesis and storage
A two-step enzymatic pathway is essential for
serotonin synthesis from the aromatic amino acid
tryptophan. Initially, tryptophan hydroxylation is
performed by two isoforms of tryptophan hydro-
xylase (TPH-1 and TPH-2), resulting in the for-
mation of 5-hydroxytryptophan [81, 93]. It has
been demonstrated that TPH-1 –/– mice exhibit
peripheral serotonin deficiency but almost nor-
mal brain levels. Tryptophan hydroxylation by
TPH-1 was found to be the rate-limiting step in
peripheral serotonin synthesis [94], while the se-
cond isoform TPH-2 is responsible for serotonin
synthesis in the brain. 5-hydroxytryptophan is
subsequently decarboxylated by the ubiquitous
enzyme amino acid decarboxylase which converts
it to serotonin [81, 93]. About 95% of serotonin in
the body is found in the gastrointestinal tract, of
which 90% is in enterochromaffin cells and 10%
in enteric neurons. The remaining serotonin (5%)
is found in the brain. Serotonin does not have the
ability to cross the membrane lipid bilayer; it has
therefore to be bidirectionally transported [93].
The serotonin reuptake transporter (SERT) is the
major protein responsible for uptake and release
of serotonin [95]. SERT is widely distributed in
the central and peripheral sympathetic nervous
system as well as in platelets, the gastrointestinal
tract and lungs [96]. Platelets are able to attract
serotonin from the gut and lung. Serotonin is pre-
sent in high concentration in platelets, where it
accumulates from the plasma via the active trans-
port system SERT. Thus, serotonin participates in
aggregation of platelets and coagulation of blood
[97, 98]. Operating as buffers, platelets maintain
low levels of free circulating serotonin. As the car-
rier and reservoir, platelets store serotonin in
dense electron-opaque granules [93]. The study
of Walther and Bader on enterochromaffin cells
report-ed two forms of serotonin storage; a minor
portion which remains outside the secretory gran-
ules, and another which is bound to proteins and
must be stored in platelets [94].
Serotonin metabolism
Serotonin in tissues can be rapidly metabo -
lised, mainly as a result of the activity of mono -
amine oxidase (MAO). In the kidney and the liver
the enzymes MAO and aldehyde dehydrogenase
convert serotonin to 5-hydroxyindoleacetic acid,
which is excreted in the urine [81]. We have 
recently shown that serotonin may mediate the
pathology of specific liver diseases. We tested the
role of serotonin in the pathogenesis of steatohep-
atitis wild-type versus TPH-1 –/– mice, both fed 
a choline-methionine-deficient diet. Despite an
almost equal degree of fatty infiltration in both
mouse strains, TPH-1 –/– mice displayed reduced
hepatocellular injury and less severe inflamma-
tion. It is known that serotonin enhances the lev-
els of reactive oxygen species and lipid peroxides
as a result of serotonin catabolism by MAO. We
concluded that serotonin promotes the progres-
sion of steatohepatitis by oxidative stress. In the
mouse strain lacking peripheral serotonin hepato-
cellular injury was decreased, with concomitant
reduction of mitochondrial damage and inflam-
mation [99]. In the central nervous system as well
as the gut, SERT plays an important role in ter-
minating transmitter action and in maintaining
transmitter homoeostasis since there is no extra-
cellular enzyme analogous to acetylcholinesterase
that could rapidly catabolise serotonin [81, 93].
Serotonin receptors
There are a wide variety of serotonin receptor
isoforms distributed in the enteric neurons, 
enterochromaffin cells, gastrointestinal smooth 
muscle cells and possibly in enterocytes, immune
tissues and hepatocytes [100, 101]. So far seven
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Figure 3
Action of serotonin in
the bowel wall. Sero-
tonin released from
stimulated entero-
chromaffin cells 
activates submucosal
intrinsic primary effe-
rent neurons (pink)
through 5-HT1P re-
ceptors. The latter
spread information to
the myenteric plexus
(blue) allowing peri-
staltic reflexes. Sero-
tonin also activates
extrinsic sensory
neurons (purple)
which relay informa-
tion to the central
nervous system.
Black arrows repre-
sent reuptake of se-
lective serotonin by
its transporter (SERT)
which is blocked by
serotonin reuptake
inhibitor (SSRI) [Adapt -
ed from: Lesurtel M,
et al. Role of sero-
tonin in the hepato-
gastrointestinal tract:
an old molecule for
new perspectives.
Cell Mol Life Sci.
2008;65(6):940–52,
and reprinted with
permission.]
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types of serotonin receptors have been recognised
[102]. The seven families of serotonin receptors
are designated 5-HT1 to 5-HT7. Serotonin re-
ceptors can also be classified into functional sub-
types which signal through different intracellular
pathways, eg cyclic adenosine monophosphate 
or inositol triphosphate pathways. The pharma-
cology of serotonin receptors is very complex.
Many drugs are used clinically, the majority of
which target serotonin receptors or serotonin
reuptake transporters (SERT). We have prev i -
ously summarised the information concerning the
types and subtypes of serotonin receptors [81].
One of the end points of our studies on the im-
pact of serotonin on liver regeneration was to
identify the serotonin receptor and subtype which
mediates serotonin signaling in liver regenera-
tion. To that end, mRNA levels of various seroto-
nin receptors after partial hepatectomy indicated
that 5-HT2 is involved in liver regeneration. In a
series of experiments using agonists and antago-
nists of serotonin receptors we were able to show
that liver regeneration is predominantely media-
ted by 5-HT2A and 5-HTB receptors [103–105].
Interconnection among serotonin, 
platelets and liver regeneration
Platelets maintain a sort of mutual coopera-
tion with serotonin. Platelets are responsible for
picking up serotonin from the gut and lungs and
provide the main peripheral storehouse of seroto-
nin [93]. On the other hand, serotonin has a mito-
genic influence on megakaryocytes via 5-HT 2
receptor [106]. Moreover, serotonin is essential
for platelet aggregation and subsequent blood
coagulation. A mitogenic circuit has been identi-
fied linking serotonin receptor 5-HT2B and the
receptor of PDGF [107, 108]. Similarly, a cross -
talk between SERT and PDGF receptor in
smooth muscle cells has been described [109]. In
1998, a study on hepatocyte cell culture showed
that serotonin causes a dose-dependent increase
in (3H)-thymidine incorporation into hepatic
DNA in the presence of insulin and EGF, indica-
ting a potential role for serotonin in liver regene-
ration [110]. Some 25 years ago Kulinskii et al. re-
ported that a serotonin precursor is able to in-
crease the endogenous serotonin level in the re-
generating liver and stimulate mitotic activity
[111].
Role of serotonin in liver regeneration
Serotonin may be involved in liver regenera-
tion at the cerebral level also. The relationship
between the functional status of the liver and the
brain has been known for centuries [81]. For ex-
ample, alteration in the serotonin-brain circuits is
well established in hepatic encephalopathy [112–
114]. An up-regulation of the brain 5-HT2C
 receptor has been observed after partial hepatec-
tomy and in hepatic neoplasia. The increased
 serotonin content and 5-HT2C receptor in the
brainstem and cerebral cortex seems to enhance
hepatocyte proliferation, possibly through the
sympathetic pathway [115]. 
Our interest in regeneration led us to investi-
gate platelets and factors stored by these cells. In
an attempt to further identify the impact of plate-
lets we identified serotonin as a mediator of regen -
eration. Experiments with serotonin antagonists
convincingly demonstrated that serotonin medi-
ated its effect via the receptor 5-HT2A and possi-
bly to a lesser degree through 5-HT2B. In an-
other approach we used knock-out mice of TPH-1
which display a normal phenotype except for a
dramatic reduction in serotonin content in plate-
lets. Following 70% hepatectomy, these mice 
failed to induce liver regeneration as measured by
proliferating hepatocytes. All parameters used to
estimate the regenerative potential consistently
indicated a loss of proliferative activity. 
Since TPH-1 –/– mice exhibit normal levels
of amino acid decarboxylase, TPH-1 –/– mice
were then treated with the serotonin precursor 
5-HTP. This led to efficient conversion to sero-
tonin which was easily detectable in blood. Con-
currently with the restoration of serotonin levels
in TPH-1 –/– mice, the regenerative potential was
rescued (fig. 4) [64]. Papadimas et al. showed that
5-HT2 receptor inhibition by ketanserin arrests
liver regeneration when administrated close to
the G1/S transition point. This finding suggests
that serotonin may be a cofactor for DNA synthe-
sis [116]. More recently we studied the impact of
platelets and serotonin in a mouse model of nor-
mothermic ischaemia/reperfusion injury of the
liver [117]. Neither inhibition of platelet function
nor platelet depletion led to a reduction in post-
ischaemic tissue injury. Postischaemic inflamma-
tion, as well as liver regeneration and conse-
quently tissue repair, were however strikingly 
impaired. In particular, platelet-derived serotonin
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Figure 4
Representative proli-
ferating cell nuclear
antigen (PCNA) stai-
ned sections from
remnant livers 
showing decreased he-
patocyte proliferation
2 days after hepatec-
tomy in TPH-1 knock-
out (TPH) compared
with wild type (WT)
mice and restoration
of liver regeneration
by serotonin reload -
ing (TPH+5HTP). 
[Adapted from: Lesur-
tel M, Graf R, Aleil B,
Walther DJ, Tian Y, Jo-
chum W, Gachet C,
Bader M, Clavien PA.
Platelet-derived sero-
tonin mediates liver
regeneration. Sci-
ence. 2006;312:104–
7.]
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was found to mediate hepatocyte proliferation,
which is an integral component of postischaemic
tissue repair. Liver regeneration and repair were
significantly impaired in platelet-depleted ani-
mals. Mice lacking peripheral serotonin (TPH-1
knock-out mice) show a failure of hepatocyte pro-
liferation after ischaemia, but otherwise display
normal tissue remodeling. The results suggest
that platelets may not cause postischaemic liver
injury, but mediate tissue repair through modula-
tion of inflammation and release of serotonin
[117].
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Conclusions and perspectives
Despite the impressive number of studies on
liver regeneration, the putative role of many mol -
ecules and cells in the pathophysiology of the 
liver and particularly liver regeneration remains
only partially known. Serotonin, platelets and
liver are unique examples of fruitful cooperation
between molecule, corpuscle and organ. Sero-
tonin and platelets are essential one for another,
with a close cross-talk with the liver. The novel
role of serotonin and platelets in liver regenera-
tion may hopefully contribute to the understand-
ing of pathways involved in liver regeneration. It
might open the door to innovative methods to
save the lives of patients in whom partial hepatec-
tomy is indicated. However, future laboratory and
clinical studies are needed to discover the  precise
action of serotonin and platelets in this process.
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